Healthcare & Life Sciences
Buzzard Pharmaceuticals
Sweden
pre-seed
pre-seed
Stage
1
Investors
About
Buzzard Pharmaceuticals is developing Isunakinra, a chimeric interleukin-1 receptor antagonist originally developed for ophthalmology and repurposed for oncology, currently in Phase 1/2 trials in combination with PD-1 checkpoint inhibitors for treating solid tumours.
Explore Buzzard Pharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.